Warning: The NCBI web site requires JavaScript to function. more...
Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy.
Palermo B, Garbelli S, Mantovani S, Giachino C.
J Autoimmune Dis. 2005 Aug 31;2:7.
Related citations
Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
Garbelli S, Mantovani S, Palermo B, Giachino C.
Pigment Cell Res. 2005 Aug;18(4):234-42. Review.
Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo.
Palermo B, Garbelli S, Mantovani S, Scoccia E, Da Prada GA, Bernabei P, Avanzini MA, Brazzelli V, Borroni G, Giachino C.
Eur J Immunol. 2005 Nov;35(11):3153-62.
High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo.
Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V.
J Exp Med. 1998 Sep 21;188(6):1203-8.
HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.
Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B, Knauss-Scherwitz E, Stevanovic S, Rammensee HG, Garbe C.
J Invest Dermatol. 2001 Jun;116(6):891-7.
Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo.
Wańkowicz-Kalińska A, van den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, Cerundolo V, Storkus WJ, Das PK.
Lab Invest. 2003 May;83(5):683-95.
Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient.
Mantovani S, Garbelli S, Palermo B, Campanelli R, Brazzelli V, Borroni G, Martinetti M, Benvenuto F, Merlini G, della Cuna GR, Rivoltini L, Giachino C.
J Invest Dermatol. 2003 Aug;121(2):308-14.
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD.
J Exp Med. 2000 Dec 4;192(11):1637-44.
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC.
J Clin Oncol. 2005 Dec 10;23(35):8978-91. Epub 2005 Oct 31.
Therapeutic implications of autoimmune vitiligo T cells.
Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, Nishimura MI, Das PK, Luiten RM, Le Poole IC.
Autoimmun Rev. 2006 Aug;5(7):486-92. Epub 2006 May 6. Review.
Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, DeBenedette MA.
J Invest Dermatol. 2003 Sep;121(3):550-6.
Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma.
Gottlieb DJ, Li YC, Lionello I, Tanzarella S, Marangolo M, Bradstock KF, Russo V, Traversari C.
Br J Cancer. 2006 Jul 17;95(2):181-8. Epub 2006 Jul 4.
Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients.
Jacobs JF, Aarntzen EH, Sibelt LA, Blokx WA, Boullart AC, Gerritsen MJ, Hoogerbrugge PM, Figdor CG, Adema GJ, Punt CJ, de Vries IJ.
Cancer Immunol Immunother. 2009 Jan;58(1):145-51. Epub 2008 Apr 5.
Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
Kiniwa Y, Fujita T, Akada M, Ito K, Shofuda T, Suzuki Y, Yamamoto A, Saida T, Kawakami Y.
Cancer Res. 2001 Nov 1;61(21):7900-7.
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.
Byrne KT, Côté AL, Zhang P, Steinberg SM, Guo Y, Allie R, Zhang W, Ernstoff MS, Usherwood EJ, Turk MJ.
J Clin Invest. 2011 May 2;121(5):1797-809. doi: 10.1172/JCI44849. Epub 2011 Apr 11.
Autoimmune aspects of depigmentation in vitiligo.
Le Poole IC, Wañkowicz-Kaliñska A, van den Wijngaard RM, Nickoloff BJ, Das PK.
J Investig Dermatol Symp Proc. 2004 Jan;9(1):68-72. Review.
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
van den Boorn JG, Konijnenberg D, Dellemijn TA, van der Veen JP, Bos JD, Melief CJ, Vyth-Dreese FA, Luiten RM.
J Invest Dermatol. 2009 Sep;129(9):2220-32. Epub 2009 Feb 26.
Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
Cui J, Bystryn JC.
Arch Dermatol. 1995 Mar;131(3):314-8.
T cell immune responses against melanoma and melanocytes in cancer and autoimmunity.
Kawakami Y, Suzuki Y, Shofuda T, Kiniwa Y, Inozume T, Dan K, Sakurai T, Fujita T.
Pigment Cell Res. 2000;13 Suppl 8:163-9.
Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, Ardigó M, Borroni G, Martinetti M, Badulli C, Necker A, Giachino C.
J Invest Dermatol. 2001 Aug;117(2):326-32.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on